Remission of mild-to-moderate asthma in Thai adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a cross-sectional observational project enrolling Thai adults aged 18 years or older with mild-to-moderate asthma. Participants complete two asthma-control questionnaires (GINA and ACT) and undergo spirometry, fractional exhaled nitric oxide (FeNO) testing, and a blood eosinophil count during a single visit. The main goals are to measure the prevalence of remission and to identify clinical or biomarker factors associated with remission in this population. Data will provide a snapshot of asthma control and physiological markers among clinic-attending adults in Pathum Thani.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* mild-to-moderate asthma
* age 18 years or older

Exclusion Criteria:

* inability to perform spirometry or fractional exhaled nitric oxide (FeNO) test

Where it's running

• Narongkorn Saiphoklang
  Pathum Thani, Changwat Pathum Thani, Thailand Recruiting
• Faculty of Medicine, Thammasat University
  Pathum Thani, Thailand Recruiting

Study contacts

• Principal investigator: Narongkorn Saiphoklang, MD — Thammasat University Faculty of Medicine
• Study coordinator: Narongkorn Saiphoklang, MD
• Email: M_narongkorn@hotmail.com
• Phone: +6629269794

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 45th Multicenter Airway Collaboration on ED initiation of Airsupra

  This trial tests whether giving Airsupra in the emergency department reduces asthma recurrence over three months for adults sent home on a short course of steroids.

  Recruiting Phase 4 Massachusetts General Hospital · Cleveland, Ohio · NCT07166939

• Chronic Respiratory Disease Participant Engagement

  This study tests whether adults with long-term lung conditions can get comfortable with a clinical trials unit and research team before joining future trials.

  Recruiting Richmond Pharmacology Limited · London · NCT07924462

• HB0056 in adults with moderate to severe asthma

  This study tests HB0056 versus a placebo to see if it helps adults with moderate to severe asthma reduce rescue inhaler use and improve symptoms.

  Recruiting at 2 sites Phase 1/2 Shanghai Huaota Biopharmaceutical Co., Ltd. · Beijing and 1 other locations · NCT07899996

• Tilrekimig (PF-07275315) for Severe Asthma: Aimed at Adults with Frequent Exacerbations

  This study tests whether tilrekimig helps people with severe asthma who have had multiple flare-ups in the past year, by comparing it to a placebo given every four weeks.

  Recruiting at 4 sites Phase 3 Pfizer · River Forest, Illinois and 11 other locations · NCT07869043

• Inhaled CHF10136 safety and pharmacokinetics in healthy adults and adults with asthma

  This first-in-human study tests inhaled CHF10136 to see if it is safe and well tolerated, how it behaves in the body, and how it affects adults with asthma compared with placebo.

  Recruiting Phase 1 Chiesi Farmaceutici S.p.A. · Leeds and 2 other locations · NCT07851623

• Biologics for Type 2 Inflammation in Asthma and COPD in Real World

  This real-world study tests whether six biologic drugs can reduce flare-ups and improve symptoms in adults with asthma or COPD treated in routine care in China.

  Recruiting Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, Shanghai Municipality · NCT07823842

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.